Discussion
The U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Winrevair (sotatercept-csrk), an approved injection therapy for adults with pulmonary arterial hypertension (PAH) marketed by Merck. The most notable change in this update is the addition of a contraindication (a…